EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer

Zhou Yang, Wei Su, Qinglin Zhang, Lili Niu, Baijie Feng, Yu Zhang, Feng Huang, Jiaxin He, Qinyao Zhou, Xin Zhou, Longjun Ma, Jingwan Zhou und 6 weitere

Advanced Science · 2025-03 · 12 (12)

DOI: 10.1002/advs.202408845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.01.2025. Verfasst von Zhou Yang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Ferroptosis, Histone Deacetylase Inhibitors, Colorectal Neoplasms, Apoptosis Regulatory Proteins. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Anticancer Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is highly resistant to ferroptosis, which hinders the application of anti‐ferroptosis therapy. Through drug screening, it is found that histone deacetylase inhibitor (HDACi) significantly sensitized CRC to ferroptosis. The combination of HDACi and ferroptosis inducers synergically suppresses CRC growth both in vivo and in vitro. Mechanically, HDACi reduces ferroptosis suppressor protein (FSP1) by promoting its mRNA degradation. Specifically, it is confirmed that HDACi specifically targets HDAC1 and promotes the H3K27ac modification of fat mass‐ and obesity‐associated gene (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), which results in significant activation of FTO and ALKBH5. The activation of FTO and ALKBH5 reduces N6‐methyladenosine (m 6 A) modification on FSP1 mRNA, leading to its degradation. Crucially, lactylation of HDAC1 K412 is essential for ferroptosis regulation. Both Vorinostat (SAHA) and Trichostatin A (TSA) notably diminish HDAC1 K412 lactylation in comparison to other HDAC1 inhibitors, exhibiting a consistent trend of increasing susceptibility to ferroptosis. In conclusion, the research reveals that HDACi decreases HDAC1 K412 lactylation to sensitize CRC to ferroptosis and that the combination of HDACi and ferroptosis inducers can be a promising therapeutic strategy for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisHistone Deacetylase InhibitorsColorectal NeoplasmsApoptosis Regulatory ProteinsHistone Deacetylase 1Cell Line, TumorHumansMaleAnimalsMiceMice, Inbred C57BLMice, Inbred BALB CRNA MethylationHistone CodeAlpha-Ketoglutarate-Dependent Dioxygenase FTOVorinostatFemaleMiddle AgedDrug Screening Assays, AntitumorMitochondrial ProteinsRNA-Binding ProteinsAlkB Homolog 5, RNA DemethylaseHydroxamic Acids

Stichwörter der Autor:innen

HDAC inhibitorN6‐methyladenosine modificationcolorectal cancerferroptosislactylation

Substanzen

Histone Deacetylase InhibitorsApoptosis Regulatory ProteinsAlpha-Ketoglutarate-Dependent Dioxygenase FTOVorinostatHistone Deacetylase 1ferroptosis suppressor protein 1, humanMitochondrial ProteinsIGF2BP1 protein, humanRNA-Binding ProteinsFTO protein, human

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Departments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu, 214043, China.
  • Department of Integrative Medicine, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, China.
  • Department of Medical Oncology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, China.

ORCID-Profile: Bing Yao

Förderung

  • Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Anticancer Association
  • Natural Science Foundation of Jiangsu Province
  • The General Program of Wuxi Medical Center, Nanjing Medical University
  • The General Program of Wuxi Medical Center
  • Major Research Projects of Taizhou Clinical Medical College
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Su, W., Zhang, Q., Niu, L., Feng, B., Zhang, Y., Huang, F., He, J., Zhou, Q., Zhou, X., Ma, L., Zhou, J., Wang, Y., Xiong, W., Xiang, J., Hu, Z., Zhan, Q., & Yao, B. (2025). Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. Advanced Science, 12(12). https://doi.org/10.1002/advs.202408845

Vancouver

Yang Z, Su W, Zhang Q, Niu L, Feng B, Zhang Y, et al. Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. Advanced Science. 2025;12(12). doi:10.1002/advs.202408845

BibTeX
@article{Yang2025,
  author = {Yang, Zhou and Su, Wei and Zhang, Qinglin and Niu, Lili and Feng, Baijie and Zhang, Yu and Huang, Feng and He, Jiaxin and Zhou, Qinyao and Zhou, Xin and Ma, Longjun and Zhou, Jingwan and Wang, Yuanrong and Xiong, Wenjing and Xiang, Jun and Hu, Zhilin and Zhan, Qiang and Yao, Bing},
  title = {Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {12},
  doi = {10.1002/advs.202408845}
}
Kostenlos starten →